Short-Term Follow-Up Study on the Efficacy and Safety of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Venous Occlusions.

Aim This study aimed to assess the short-term safety and efficacy of intravitreal bevacizumab in the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO). Methods A prospective interventional study was conducted from July to December 2023, involving 30 patients with ME due to RVO. Intravitreal bevacizumab (1.25 mg/0.05 mL) was administered every 4-6 weeks. Follow-up evaluations included comprehensive ophthalmic examinations and central retinal thickness (CRT) measurements using optical coherence tomography, performed at baseline and throughout the six-month follow-up. Results The study included 30 patients with a mean age of 55.3 ± 10.21 years. Baseline CRT was 568.53 ± 156.29 µm, which significantly reduced to 309.53 ± 89.11 µm after six months. Best-corrected visual acuity (BCVA) improved from 1.14 ± 0.38 logMAR at baseline to 0.53 ± 0.19 logMAR at six months (p < 0.001). BCVA improvement was observed in 86.5% of patients. A gain of more than three lines was noted in 36.6% (n = 11), two or more lines in 46.6% (n = 14), and one line in 3.33% (n = 1). On average, patients received three injections (range: 1-3). No improvement was seen in 10% (n = 3), while deterioration occurred in 3.33% (n = 1). Conclusion Intravitreal bevacizumab appears to be a safe and effective short-term treatment for reducing ME and improving visual acuity in patients with RVO, based on outcomes observed at a tertiary referral eye hospital.